Hence, our data appear in a new light as we previously demonstrated that pharmacological activation of PPAR-α or its cardiomyocyte-specific overexpression was detrimental in ischemic cardiomyopathy [24,25]. This evidence concerns the gene PPARA and ischemic cardiomyopathy.